Takeda Pharmaceutical Company Limited (LON:0A87)

London flag London · Delayed Price · Currency is GBP · Price in USD
14.90
+0.63 (4.41%)
At close: Mar 4, 2025
2.26%
Market Cap 34.92B
Revenue (ttm) 23.26B
Net Income (ttm) 1.06B
Shares Out n/a
EPS (ttm) 0.66
PE Ratio 33.03
Forward PE n/a
Dividend 0.41 (2.76%)
Ex-Dividend Date Sep 30, 2024
Volume 1,682
Average Volume 2,136
Open 14.90
Previous Close 14.27
Day's Range 14.90 - 14.90
52-Week Range 10.01 - 11.99
Beta n/a
RSI 75.98
Earnings Date May 8, 2025

About LON:0A87

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 49,281
Stock Exchange London Stock Exchange
Ticker Symbol 0A87
Full Company Profile

Financial Performance

In 2023, LON:0A87's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.